8-K - Disc Medicine, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Disc Medicine, Inc. approved a restructuring plan on February 26, 2026, reducing its workforce by approximately 20% primarily in commercial and supporting functions, following an FDA complete response letter on February 13, 2026, for its bitopertin NDA. The Company expects $2.0 million in aggregate charges, mainly severance, in Q1 2026.

Key Takeaways

1Board approved Restructuring Plan on February 26, 2026

2Workforce reduction of approximately 20%

3Reductions primarily in commercial functions and certain supporting functions

4Triggered by FDA complete response letter on February 13, 2026, for bitopertin NDA treating erythropoietic protoporphyria and X-linked protoporphyria

5Expected aggregate charges of $2.0 million, primarily severance

6Implementation to complete in Q2 2026; charges primarily in Q1 2026

Current Report Details

Event Type

Impairment

Disclosure

Mandatory

Variant

8-K

Items Reported

2.05

Costs Associated with Exit or Disposal Activities. On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management

Impairment

Exhibits (1)

8-K